Search from website
Search from website
Icosagen has implemented a toolbox of diverse antibody discovery technology platforms to yield specific high affinity antibodies for any target class. To extract highly selective binders against small molecules, membrane proteins (using pseudotyped VLPs), and recombinant proteins, we combine in vivo and in vitro methods, from B-cell cloning to fully synthetic phage libraries.
Based on state-of-the-art high-throughput analytical capabilities, these antibodies can then be further optimized, formatted into any desired frameworks and seamlessly produced from milligrams to kilograms.
Our phage display antibody discovery service, which utilizes synthetic libraries customized for various targets, is a powerful high-throughput and cost-effective in vitro platform for the rapid identification and characterization of high-quality antibodies.
Phage display in combination with in vivo-immunization and our in-house B-cell cloning platform HybriFree®, generates diverse sets of highly specific, functional and non-overlapping epitope antibodies.
Our proprietary HybriFree technology is based on B-cell cloning, and is used for efficient discovery of monoclonal antibodies and their immediate production in mammalian cells. HybriFree makes antibody discovery rapid and flexible, and allows cloning antibodies even from recovered patients’ PBMCs and existing hybridomas.
All antibodies discovered through HybriFree platform can readily be produced transiently at mg to gram range or developed into stable high producer CHO cell lines.
REMEMBER: ANTIGEN MATTERS! Even the smallest difference between an antigen and the natural target protein will affect the antibody specificity and biological function.
Icosagen-discovered antibodies can be used for IVD purposes or developed as biopharmaceutical drug candidates.
We clone antibodies from hybridomas, provided by our customers, and produce them at requested scales.
In addition, we deliver the cDNA sequence encoding the antibody variable heavy (VH) and light (VL) domains.
We have implemented different immunization technology platforms, which are specifically designed to tackle diverse antigen classes. While immunizations with soluble recombinant proteins are often highly effective, more complex targets, such as multi-pass transmembrane proteins, present a serious challenge, as they are difficult to purify in native 3D-structure.
To overcome this, we engineered a proprietary display & discovery platform, that combines multi-pass transmembrane protein pseudotyped VLPs with nucleic acid immunization.
With this, and over 15 years of experience in DNA immunizations,we simply know how to create specific and functional affinity ligands with chickens and rabbits.
© 2023 Icosagen
